-
公开(公告)号：US20060167081A1
公开(公告)日：2006-07-27
申请号：US10528419
申请日：2003-10-23
申请人： Xavier Billot , Jean-Luc Beaunard , Yongxin Han , Robert Young , John Colucci , Mario Girard , Marie-Claire Wilson
发明人： Xavier Billot , Jean-Luc Beaunard , Yongxin Han , Robert Young , John Colucci , Mario Girard , Marie-Claire Wilson
IPC分类号： A61K31/4015 , C07D207/24 , A61K31/4025 , C07D403/02
CPC分类号： C07D403/06
摘要： This invention relates to potent selective agonists of the EP, subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
摘要翻译： 本发明涉及EP的有效选择性激动剂，前列腺素E2受体的亚型，它们在治疗青光眼中的用途或制剂以及与患者眼睛中眼内压升高有关的其它病症。 本发明还涉及本发明化合物用于介导成骨细胞和破骨细胞的骨建模和重塑过程的用途。
-
2.发明申请Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma 失效用作治疗青光眼的ep4受体激动剂的恶唑烷-2-酮和噻唑烷-2-酮衍生物公开(公告)号：US20060154899A1
公开(公告)日：2006-07-13
申请号：US10521508
申请日：2003-08-25
申请人： Yongxin Han , John Colucci , Xavier Billot , Marie-Claire Wilson , Robert Young
发明人： Yongxin Han , John Colucci , Xavier Billot , Marie-Claire Wilson , Robert Young
IPC分类号： A61K31/426 , A61K31/421 , C07D417/02 , C07D413/02
CPC分类号： C07D263/20 , C07D263/24 , C07D277/14 , C07D413/06 , C07D413/10 , C07D413/14 , C07D417/06 , C07D417/10
摘要： This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
摘要翻译： 本发明涉及前列腺素E2受体的EP4N4亚型的有效选择性激动剂，它们在治疗青光眼中的用途或制剂以及与眼睛中的眼内压升高有关的其它病症 患者。 本发明还涉及本发明化合物用于介导成骨细胞和破骨细胞的骨建模和重塑过程的用途。
-
3.发明申请1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma 审中-公开1,5-分布的吡咯烷-2-酮衍生物，用作眼部疾病如青光眼的ep4受体激动剂公开(公告)号：US20050239872A1
公开(公告)日：2005-10-27
申请号：US10511736
申请日：2003-06-02
申请人： Xavier Billot , Robert Young , Yongxin Han
发明人： Xavier Billot , Robert Young , Yongxin Han
IPC分类号： C07D403/06 , A61K31/13 , A61K31/137 , A61K31/138 , A61K31/382 , A61K31/4015 , A61K31/41 , A61K31/416 , A61K31/4164 , A61K31/4168 , A61K31/4178 , A61K31/433 , A61K31/4412 , A61K31/498 , A61K31/5377 , A61K31/5575 , A61K31/559 , A61K45/00 , A61K45/06 , A61P3/14 , A61P19/00 , A61P19/02 , A61P19/08 , A61P19/10 , A61P25/02 , A61P27/02 , A61P27/06 , A61P29/00 , A61P35/00 , A61P43/00 , C07D207/26 , C07D403/12
CPC分类号： A61K31/41 , A61K31/4015 , A61K45/06 , C07D403/12 , A61K2300/00
摘要： This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors of formula (1), their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of the patient.
摘要翻译： 本发明涉及式（1）的前列腺素E2受体的EP 4亚型的有效选择性激动剂，它们在治疗与眼内压升高有关的青光眼和其它病症中的用途或制剂 在病人眼中。
-
公开(公告)号：US20060270721A1
公开(公告)日：2006-11-30
申请号：US11498124
申请日：2006-08-02
申请人： Yongxin Han , John Colucci , Xavier Billot , Marie-Claire Wilson , Robert Young
发明人： Yongxin Han , John Colucci , Xavier Billot , Marie-Claire Wilson , Robert Young
IPC分类号： A61K31/426 , A61K31/421
CPC分类号： C07D263/20 , C07D263/24 , C07D277/14 , C07D413/06 , C07D413/10 , C07D413/14 , C07D417/06 , C07D417/10
摘要： This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
摘要翻译： 本发明涉及前列腺素E2受体的EP4N4亚型的有效选择性激动剂，它们在治疗青光眼中的用途或制剂以及与眼睛中的眼内压升高有关的其它病症 患者。 本发明还涉及本发明化合物用于介导成骨细胞和破骨细胞的骨建模和重塑过程的用途。
-
5.发明授权Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma 失效用作治疗青光眼的EP4受体激动剂的恶唑烷-2-酮和噻唑烷-2-酮衍生物公开(公告)号：US07109223B2
公开(公告)日：2006-09-19
申请号：US10521508
申请日：2003-08-25
申请人： Yongxin Han , John Colucci , Xavier Billot , Marie-Claire Wilson , Robert Young
发明人： Yongxin Han , John Colucci , Xavier Billot , Marie-Claire Wilson , Robert Young
IPC分类号： A01N43/74 , A01N43/713 , A01N43/76 , C07D277/04 , C07D257/04 , C07D263/04
CPC分类号： C07D263/20 , C07D263/24 , C07D277/14 , C07D413/06 , C07D413/10 , C07D413/14 , C07D417/06 , C07D417/10
摘要： This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
摘要翻译： 本发明涉及前列腺素E2受体的EP4N4亚型的有效选择性激动剂，它们在治疗青光眼中的用途或制剂以及与眼睛中的眼内压升高有关的其它病症 患者。 本发明还涉及本发明化合物用于介导成骨细胞和破骨细胞的骨建模和重塑过程的用途。
-
公开(公告)号：US20050227969A1
公开(公告)日：2005-10-13
申请号：US11146992
申请日：2005-06-07
申请人： Xavier Billot , John Colucci , Yongxin Han , Marie-Claire Wilson , Robert Young
发明人： Xavier Billot , John Colucci , Yongxin Han , Marie-Claire Wilson , Robert Young
IPC分类号： A61K31/4412 , A61K31/558 , A61P27/06 , C07D211/54 , C07D211/74 , C07D211/76 , C07D265/04 , C07D265/10 , C07D279/06 , C07D401/06 , C07D409/06
CPC分类号： C07D211/74 , C07D211/76 , C07D265/10 , C07D401/06 , C07D409/06
摘要： This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
摘要翻译： 本发明涉及前列腺素E2受体的EP 4亚型的有效选择性激动剂，它们在治疗青光眼和其它病症中的用途或制剂，其与眼睛中眼内压升高有关 病人。 本发明还涉及本发明化合物用于介导成骨细胞和破骨细胞的骨建模和重塑过程的用途。
-
公开(公告)号：US20090258918A1
公开(公告)日：2009-10-15
申请号：US12455971
申请日：2009-06-10
申请人： Xavier Billot , Robert N. Young , Yongxin Han
发明人： Xavier Billot , Robert N. Young , Yongxin Han
IPC分类号： A61K31/41 , C07D257/04 , A61P25/00
CPC分类号： A61K31/41 , A61K31/4015 , A61K45/06 , C07D403/12 , A61K2300/00
摘要： This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient.
摘要翻译： 本发明涉及前列腺素E2受体的EP4亚型的有效选择性激动剂，它们在治疗与患者眼睛中眼内压升高有关的青光眼和其它病症中的用途或制剂。
-
公开(公告)号：US07053085B2
公开(公告)日：2006-05-30
申请号：US10797257
申请日：2004-03-10
IPC分类号： C07D265/06 , C07D265/32 , A61K31/5355 , A61K31/535 , A61P27/06
CPC分类号： C07D211/74 , C07D211/76 , C07D265/10 , C07D401/06 , C07D409/06
摘要： This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
摘要翻译： 本发明涉及前列腺素E2受体的EP 4亚型的有效选择性激动剂，它们在治疗青光眼和其它病症中的用途或制剂，其与眼睛中眼内压升高有关 病人。 本发明还涉及本发明化合物用于介导成骨细胞和破骨细胞的骨建模和重塑过程的用途。
-
公开(公告)号：US20110237511A1
公开(公告)日：2011-09-29
申请号：US13152586
申请日：2011-06-03
IPC分类号： A61K38/23 , C07D211/76 , C07D409/06 , C07D401/06 , C07D265/10 , A61K31/45 , A61K31/4535 , A61K31/454 , A61K31/535 , A61K31/5377 , A61K31/4704 , A61K38/17 , A61K31/59 , A61K31/565 , A61P35/04 , A61P35/00 , A61P19/10 , A61P19/08 , A61P7/10 , A61P27/02 , A61P27/06 , A61P9/12
CPC分类号： C07D211/74 , C07D211/76 , C07D265/10 , C07D401/06 , C07D409/06
摘要： This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
摘要翻译： 本发明涉及前列腺素E2受体的EP4亚型的有效选择性激动剂，它们在治疗青光眼和其它病症中的用途或其制剂，其与患者眼睛中的眼内压升高有关。 本发明还涉及本发明化合物用于介导成骨细胞和破骨细胞的骨建模和重塑过程的用途。
-
公开(公告)号：USRE42562E1
公开(公告)日：2011-07-19
申请号：US11796044
申请日：2007-04-26
IPC分类号： C07D265/06 , C07D265/32 , A61K31/5355 , A61K31/535 , A61P27/06
CPC分类号： C07D211/74 , C07D211/76 , C07D265/10 , C07D401/06 , C07D409/06
摘要： This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
摘要翻译： 本发明涉及前列腺素E2受体的EP4亚型的有效选择性激动剂，它们在治疗青光眼和其它病症中的用途或其制剂，其与患者眼睛中的眼内压升高有关。 本发明还涉及本发明化合物用于介导成骨细胞和破骨细胞的骨建模和重塑过程的用途。
-
-
-
-
-
-
-
-
-
搜索结果
75 条记录 (耗时 0.025 秒)
